These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37968926)

  • 21. Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review.
    Puig L; Morales-Múnera CE; López-Ferrer A; Geli C
    Dermatology; 2012; 225(1):14-7. PubMed ID: 22890275
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study.
    Schett G; Chen W; Gao S; Chakravarty SD; Shawi M; Lavie F; Zimmermann M; Sharaf M; Coates LC; Siebert S
    Arthritis Res Ther; 2023 Aug; 25(1):150. PubMed ID: 37587493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DiGeorge syndrome presenting with palmoplantar pustules: Comparative analysis of serum IL-22, NETs and IL-8 with usual palmoplantar pustulosis.
    Ogura Y; Kondo S; Suzuki T; Otsuka M; Inuzuka M; Honda T; Tokura Y
    J Dermatol; 2024 May; 51(5):731-734. PubMed ID: 38111339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of biological agents to treat patients with palmoplantar pustulosis: A systematic scoping review.
    Zhang M; Hua L; Hong S; Sun X; Zhou Y; Luo Y; Liu L; Wang J; Wang C; Lin N; Li X
    Int Immunopharmacol; 2023 Sep; 122():110553. PubMed ID: 37480749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Palmoplantar Pustulosis: A Systematic Review of Risk Factors and Therapies.
    Heidemeyer K; May Lee M; Cazzaniga S; Yawalkar N; Naldi L
    Psoriasis (Auckl); 2023; 13():33-58. PubMed ID: 37772169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nail involvement features in palmoplantar pustulosis.
    Kim M; Yang S; Kim BR; Youn SW
    J Dermatol; 2021 Mar; 48(3):360-365. PubMed ID: 33305841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Palmoplantar pustulosis: Current understanding of disease definition and pathomechanism.
    Murakami M; Terui T
    J Dermatol Sci; 2020 Apr; 98(1):13-19. PubMed ID: 32201085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Upadacitinib in nail psoriasis: a case report.
    Wang N; Yang Q; Liu Y; Liu H
    J Dermatolog Treat; 2023 Dec; 34(1):2246604. PubMed ID: 37661936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical characteristics of pustulotic arthro-osteitis in Korea.
    Kim M; Kim M; Kim JW; Kim BR; Youn SW
    J Dermatol; 2022 Aug; 49(8):762-768. PubMed ID: 35510638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Refractory Palmoplantar Pustulosis Successfully Treated with JAK Inhibitor Tofacitinib: A Case Series.
    Xu Q; Wang X; Yang A; Wei G
    Infect Drug Resist; 2023; 16():5165-5172. PubMed ID: 37581169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pustular Psoriasis and Associated Musculoskeletal Disorders.
    Duffin KC; Bachelez H; Mease PJ; Rosen C; Garg A; Zudak E; Elkayam O; Merola JF; Chau J; Kishimoto M; Furer V; Helliwell PS
    J Rheumatol Suppl; 2021 Jun; 97():34-38. PubMed ID: 34074664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis.
    Fragoulis GE; Siebert S
    Musculoskeletal Care; 2022 Nov; 20 Suppl 1(Suppl 1):S12-S21. PubMed ID: 36069174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Burden of disease: psoriasis and psoriatic arthritis.
    Boehncke WH; Menter A
    Am J Clin Dermatol; 2013 Oct; 14(5):377-88. PubMed ID: 23771648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel treatment for psoriatic arthritis: Janus kinase inhibitors.
    Chen M; Dai SM
    Chin Med J (Engl); 2020 Apr; 133(8):959-967. PubMed ID: 32209886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study.
    McInnes IB; Kato K; Magrey M; Merola JF; Kishimoto M; Pacheco-Tena C; Haaland D; Chen L; Duan Y; Zueger P; Liu J; Lippe R; Pangan AL; Behrens F
    RMD Open; 2021 Oct; 7(3):. PubMed ID: 34663636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biologic therapies associated with development of palmoplantar pustulosis and palmoplantar pustular psoriasis: a systematic review.
    Lu JD; Lytvyn Y; Mufti A; Zaaroura H; Sachdeva M; Kwan S; Abduelmula A; Kim P; Yeung J
    Int J Dermatol; 2023 Jan; 62(1):12-21. PubMed ID: 35128653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
    Charles-Schoeman C; Choy E; McInnes IB; Mysler E; Nash P; Yamaoka K; Lippe R; Khan N; Shmagel AK; Palac H; Suboticki J; Curtis JR
    RMD Open; 2023 Nov; 9(4):. PubMed ID: 37945286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relative efficacy and safety of Janus kinase inhibitors for the treatment of active psoriatic arthritis: a network meta-analysis.
    Lee YH; Song GG
    Z Rheumatol; 2023 Jun; 82(5):408-416. PubMed ID: 34716775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. English version of Japanese guidance for the use of oral Janus kinase inhibitors (JAK1 and TYK2 inhibitors) in the treatments of psoriasis.
    Saeki H; Mabuchi T; Asahina A; Abe M; Igarashi A; Imafuku S; Okubo Y; Komine M; Takahashi K; Torii H; Morita A; Yotsuyanagi H; Watanabe A; Ohtsuki M;
    J Dermatol; 2023 May; 50(5):e138-e150. PubMed ID: 37132187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of Axial Spondyloarthritis - Insights into Upadacitinib.
    Braun J; Kiltz U; Baraliakos X
    Drug Des Devel Ther; 2022; 16():3609-3620. PubMed ID: 36268520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.